Roche’s lung cancer data look good, so why didn’t the market react to clinical trial results?
Roche’s anti-PD-L1 drug Tecentriq took a step closer to regulatory approval as a combination drug for untreated non-small cell lung cancer patients. So why weren’t investors impressed?